{"contentid": 488204, "importid": NaN, "name": "Omega in $126 million Series C financing", "introduction": "Privately-held US biotech Omega Therapeutics has closed an upsized Series C financing of $126 million.", "content": "<p>Privately-held US biotech Omega Therapeutics has closed an upsized Series C financing of $126 million.</p>\n<p>Proceeds will support the advancement of the company&rsquo;s lead epigenomic controller candidate, OTX-2002, into Investigational New Drug (IND)-enabling studies.</p>\n<p><span class=\"pullQuote\">\"Omega is at a pivotal stage of its development, as it prepares to debut several new pipeline assets and advance each toward clinical trials\"</span>The money will help to advance the next wave of new pipeline therapeutics that it expects to be generated by the Omega Epigenomic Programming platform, with an initial focus on oncology, regenerative medicine, inflammation, autoimmune, metabolic and rare genetic diseases.</p>\n<p>Proceeds will also be used to continue developing the Omega Epigenomic Programming platform and to build a manufacturing footprint.</p>\n<p>Joining Flagship Pioneering, Omega&rsquo;s institutional founder and principal backer, are leading life science investors including Invus, Fidelity Management &amp; Research company, funds and accounts managed by BlackRock, Cowen, Point72, Logos Capital, Mirae Asset Capital and other undisclosed new and returning institutional investors.</p>\n<p>With this financing, Omega has raised more than $210 million since its founding in 2017.</p>\n<p>Mahesh Karande, president and chief executive of Omega, said: &ldquo;Omega is at a pivotal stage of its development, as it prepares to debut several new pipeline assets and advance each toward clinical trials. We look forward to partnering with our new and existing investors to build out a robust pipeline, bring exciting new medicines to patients in need, and significantly grow value for all of our stakeholders.&rdquo;</p>", "date": "2021-03-30 15:53:00", "meta_title": NaN, "meta_keywords": "Omega, financing, million, Series, therapeutics, pipeline, advance, epigenomic, Privately-held, biotech, closed, upsized, stage, pivotal, debut, assets", "meta_description": "Privately-held US biotech Omega Therapeutics has closed an upsized Series C financing of $126 million.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-30 15:50:42", "updated": "2021-03-30 16:27:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/omega-in-126-million-series-c-financing", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "omega_therapeutics_large.png", "image2id": "omega_therapeutics_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Autoimmune Disorders, Inflammatory diseases, Metabolics, Oncology, Rare diseases, Regenerative Medicine", "topic_tag": "Business Financing, Research", "geography_tag": "USA", "company_tag": "Omega Therapeutics", "drug_tag": "OTX-2002", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-30 15:53:00"}